If you were developing a new “broad-spectrum” antibiotic to kill a wide variety of bacteria, which cell structures and pathways would you target? Which of those targets also occur in eukaryotic cells, and why is that important? How would your strategy change if you were designing a new “narrow-spectrum” antibiotic active against only a few types of bacteria?